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A fifth of patients with primary degenerative mitral regurgitation continue to present with de novo ventricular dysfunction following sur-
gery and higher rates of heart failure, morbidity, and mortality. This raises questions as to why the left ventricle (LV) might fail to recover
and has led to support for better LV characterization; cardiac magnetic resonance (CMR) may play a role in this regard, pending further
research and outcome data. CMR has widely acknowledged advantages, particularly in repeatability of measurements of volume and ejec-
tion fraction, yet recent guidelines relegate its use to cases where there is discordant information or poor-quality imaging from echocardi-
ography because of the lack of data regarding the CMR-based ejection fraction threshold for surgery and CMR-based outcome data. This
article reviews the current evidence regarding the role of CMR in an integrated surveillance and surgical timing programme.
...................................................................................................................................................................................................
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Introduction
Despite clear American Heart Association/American College of
Cardiology/European Society of Cardiology (AHA/ACC/ESC) guide-
lines on the timing of surgery, a fifth of patients with severe primary
mitral regurgitation (MR) continue to present post-operatively with
reduced ejection fraction and an increased risk of congestive cardiac
failure.1,2 These data raise questions regarding the sole use of 2D
echocardiography-based dimensions and ejection fraction as Class 1
indications for surgery. Recent guidelines by the American Society of
Echocardiography in collaboration with the Society for
Cardiovascular Magnetic Resonance acknowledged the role of car-
diac magnetic resonance (CMR) but relegated its use to cases where
there is discordant information or poor-quality imaging on echo.3
CMR has widely acknowledged advantages in monitoring size and
function of the LV, and there are preliminary data highlighting dis-
crepancies in quantification of primary MR with echo. This article
reviews the current evidence on the role of CMR in an integrated
surveillance and surgical timing programme.
Anatomical assessment of MR:
can echo be rivalled?
Complete analysis of the components of the mitral valve (MV) and
subvalvar apparatus are required to identify the lesion, aetiology, and
type of dysfunction in MR. Such an analysis requires assessment of
the leaflets, annulus, chordae tendonnae, and papillary muscles.
Identification of prolapse and assessment
of leaflets
Assessment and measurements on 2D and 3D echo offer high accur-
acy and reproducibility due to high-temporal resolution and
improved frame rates. While 2D transthoracic echo (TTE) is recom-
mended as the first-line examination, 3D TTE acquisitions provide in-
cremental value in establishing the lesion, leaflet, and location of the
segments involved, with an accuracy that is equivalent to 2D multi-
plane transoesophageal echo (TOE).4 3D TOE has the greatest over-
all accuracy with a higher specificity in the segmental localization of
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defects (92.8%) compared with surgical findings and is particularly ef-
fective in the localization of flail defects (99%). Moreover, 3D TOE
has the advantage of producing both static and dynamic measure-
ments of MV anatomy and pathology that can predict both the com-
plexity of repair and likely outcome at surgery, including prolapse
height, prolapse volume, and anterior leaflet surface area and leaflet
length (Supplementary data online, Table S1).4,5
Data comparing echo with CMR for the detection of leaflet abnor-
malities are limited. CMR requires a dedicated set of sequences that
requires time and experience and those most commonly used have
lower temporal and spatial resolution than echo.6 However, using a
set protocol with dedicated valve imaging planes on CMR, one group
diagnosed the presence of posterior mitral valve leaflet prolapse with
100% sensitivity and anterior mitral valve leaflet prolapse with 78%
sensitivity when compared with 2D TTE, but the study did not com-
pare accuracy to surgical findings.7 In another study of 27 patients,
CMR correctly identified the presence or absence of a segmental de-
fect in 82% comparing to 2D TTE.8 In 43 patients using surgical find-
ings as the reference standard, results on CMR and 2D TOE were
concordant in terms of diagnosing prolapse and identification of the
leaflet at fault but data on identification of the scallop at fault was not
given.9 Correct identification not only of the leaflet at fault but of the
specific scallop is now the minimum standard in preoperative assess-
ment of primary MR, and the degree of accuracy and amount of infor-
mation provided by 3D echo far surpasses that of CMR in this
respect. Moreover, CMR cannot yet deliver the same high-quality en-
face view that is standard in 2D and 3D echo as part of pre-operative
planning.
Annulus
Two difficulties have been encountered in establishing an optimal
imaging strategy for the MV annulus: firstly, the surgical reference for
sizing is performed in a de-aired heart, and therefore, these measure-
ments do not correspond to ‘live’ imaging; secondly, 3D TOE has
highlighted that the annulus is not fixed but dynamic throughout the
cardiac cycle, with change in size (early systolic area contraction) and
shape (deepening of the saddle-shape). There are no data on the ac-
curacy of CMR-based assessment of MV annular dimensions com-
pared with echo or surgical findings in primary MR, meaning that 3D
echo is currently gold standard.10
Assessment of chordae and papillary
muscles
The location and attachment of the primary, secondary, and tertiary
chordae are critical to current surgical strategies for repair. The loca-
tion, length, and thickness of the mitral chordae are best measured
on 2D echo due to higher spatial resolution and are best visualized
on 2D TOE from the transgastric view.11 Although the subvalvular
apparatus, including chordae, leaflets, and papillary muscle attach-
ments, can be seen on CMR, detailed assessment is much more lim-
ited compared with 2D echo which, remains the modality of choice.
Assessment of papillary muscle (PM) location, displacement, and
function (whether ruptured, fibrotic, infarcted, or displaced) is im-
portant for establishing the mechanism of the MR yet there are no
comparative data on the utility of echo and CMR in this regard. Data
with echo are more compelling; 2D TTE has demonstrated abnormal
superior displacement of PM tips during systole as one mechanism
contributing to MV prolapse.12 3D TOE has demonstrated PM dis-
placement secondary to progressive LV dilatation with resultant leaf-
let tethering, as well as the relationship between PMs and LV wall
which may assist surgical planning of MV repair.13 Although CMR can
accurately locate, measure size, and track PM displacement, as well as
identify PM infarction/fibrosis,14 the clinical implications of these find-
ings in primary degenerative MR remain unclear.
In summary, echo remains the current gold standard for anatomic
and functional assessment of the MV apparatus in primary MR, ena-
bling precise localization of the abnormality and determination of
aetiology, as well as being key for planning and guiding intervention.
There are a few small studies on the role of CMR in defining mitral
apparatus anatomy but restricted spatial and temporal resolution
remains a limiting factor.
Severity of MR: a potential role for
CMR?
Echo is the principal imaging modality to diagnose and establish sever-
ity of MR but requires integration of multiple qualitative, semi-quanti-
tative, and quantitative parameters.3 The echocardiographer must
also weigh up the different specificity of each parameter and is
encouraged to use quantitative measures to grade MR severity,
including pulsed Doppler, volumetric and flow convergence [prox-
imal isovelocity surface area (PISA)] methods (Supplementary data
online, Table S1). Despite the recommendation to quantify MR, a re-
cent communication from the ACC recognized that inadequate qual-
ity of echo may be a barrier to optimal care of almost a quarter of
patients with MR and that many decisions regarding severity of MR
are still made on echo by visually estimating severity based on colour,
with a minority of reports providing regurgitant volumes and frac-
tion.15 Even when recommendations are followed, quantification by
echo is subject to several errors, including practical issues such as
over-estimation of non-holosystolic Doppler profiles and failure to
account for regurgitant blood volume on the atrial side of the MV
annulus in patients with extensive bileaflet prolapse which is not ac-
countable when using a Simpson’s method for quantifying LV end-
systolic volume.16 Pulsed Doppler methods to estimate differential
LV and aortic stroke volumes are valuable, particularly in the pres-
ence of multiple jets, constrained and non-holosystolic jets when
PISA and vena contracta (VC) are less reliable. However, limitations
include the combination of several parameters that carry intrinsic
error and increase as the root sum square so that, even under re-
search conditions, the volume bias and limits of agreement between
observers for aortic stroke volume (4.7± 29.1 mL) and mitral stroke
volume (2.9± 19.6mL) are poor.17 Likewise, questions have been
raised about the reliability of flow convergence even amongst experts
from university institutions.18 When grading MR as severe or non-
severe, the overall interobserver agreement for PISA measurements
was poor: 0.37 [95% confidence interval (CI): 0.16–0.58]. A significant
source for this variation is the frame-to-frame and beat-to-beat vari-
ation in PISA distance which have been quantified as 15–25% even in
expert hands, highlighting the importance of multi-frame averaging
[estimated at approximately 35 beats if clinicians require an effective
regurgitant orifice area (EROA) with CI of ±10%] if precision is to be
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achieved.19 While this may be impractical in routine clinical practice,
any degree of averaging will reduce variation. Additionally, the future
validation and adoption of automated averaging EROA20 and auto-
mated 3D colour flow Doppler quantification systems21 may en-
hance the accuracy and consistency of echocardiographic MR
quantification.
In contrast to current guideline-based echocardiographic approaches,
estimation of MR severity by CMR (Supplementary data online, Table
S1) is reliant on a small number of quantitative methods that have been
validated against other reference standards, including cardiac catheteriza-
tion,22 quantitative Doppler TTE,23 and current single-frame 2D PISA-
based methods.24 Studies that compare the reproducibility of TTE and
CMR in the same patients however are limited. In a prospective study of
26 patients with a range of severity inMR, regurgitant volumewas similar
between quantitative Doppler, flow convergence TTE, and CMR, but
variability in measurements by all methods was poor between observers
[Doppler -10 mL (95% CI -76 to 56mL); PISA: -4mL (-21 to 13mL);
and CMR 0.7mL (-30 to 32mL)].24 Interobserver variability of regurgi-
tant fraction was significantly lower by CMR than TTE in a retrospective
study of 70 patients (0.1± 7.3% vs. -5.5± 15%) although this finding only
applied to re-analysis of acquired datasets.25 Another retrospective
study comparing quantitative assessment of MR highlighted that quantifi-
cation by echowas often not achievable in practice, being feasible only in
44 out of 72 patients.26 Where an integrative approach to
echocardiographic-based MR severity grading has been applied as per
American Society of Echocardiography guidance, intra- and interob-
server disagreement is quoted at 20% and 40% on echo.27 On CMR
based categorization (severe MR defined as regurgitant volume
>_60mL), discordance is reported at 5% and 10%, respectively.
Furthermore, in this prospective observational study of 258 asymptom-
atic patients, a quarter of patients had a discrepant degree of severity
diagnosed on CMR and echo, with the CMR classification offering super-
ior prognostic value for predicting the composite endpoint of mortality
orMV surgery during themedian follow-up of 5 years.27 However, there
are also limitations to quantifying MR severity by CMR, including the
presence of non-compensated Eddy current-induced fields, variability in
volumetric analysis according to placement of the basal slice and in phase
velocity mapping according to the plane used for measuring aortic
flow.28 4D flow phase contrast CMRmay be able to overcome some of
these limitations but this currently remains a research tool.29
Additionally, echo can easily be combined with exercise testing for cases
where exertional symptoms are disproportionate to resting haemo-
dynamics,30 whereas this is understandably more challenging for CMR.
In summary (Figure 1), CMR quantification of MR is simple, feasible in a
greater proportion of patients and from the limited comparative studies,
may be more reproducible. However, outcome data remain limited and
present guidelines are derived from large echo-based outcome studies
such that more data are needed which compare the primary analysis of
newly acquired CMR datasets.
Are severity cut-offs equivalent on echo
and CMR?
Several studies have found a discrepancy in the grading of severity be-
tween CMR and TTE, with a tendency for echo to over-estimate pri-
mary MR (Table 1).26,27,31 These data support a role for CMR in such
cases where echo grading is qualitative, indeterminate, or incomplete
(see Table 2). In recent small prospective studies, CMR quantification
of regurgitant volume better predicted LV remodelling after surgery
[change in left ventricular end-diastolic volume (LVEDV), r=0.85;
P<0.0001]; whereas no correlation was present for echo (r=0.32;
P=0.1).31 In addition, a post-operative decrease in LV internal dimen-
sions most closely correlated (r=0.69) with the regurgitant volume
by CMR.26 These studies of post-operative outcome both suggested
that a lower threshold for severe MR grading may be needed for
CMR and is supported by two recent prospective observational stud-
ies. In 109 asymptomatic MR patients, severe MR was defined as a
regurgitant volume >55mL or regurgitant fraction >40% using the
SVol-AVf method on baseline CMR.
32 Using these cut-offs, over a
mean follow-up of 2.5 years, subjects with a regurgitant volume of
>55mL had a surgery-free survival rate of 21% at 5 years compared
with 91% in those with regurgitant volume <_55mL. Similarly a se-
cond study on 258 asymptomatic patients found a regurgitant volume
of >_50mL to possess 77% sensitivity and 78% specificity for identify-
ing mortality or indication for MV surgery over a median follow-up of
5 years.27
In summary, single measures of MR severity by echo have wide lim-
its of agreement therefore a multi-parametric approach must be used.
While CMR has limitations, it uses fewer parameters and observation-
al data suggest it is better at predicting severity, need for surgery and
LV outcomes, although standardized CMR cut-off points for severe
MR need to be agreed upon. Importantly, it remains to be seen
whether surgical intervention based on CMR parameters alone can
lead to an improvement in patient outcome compared with echo.
Chamber size and function:
Achilles heel of echo?
Serial TTE is the recommended method for measurement of cham-
ber size and function in primary MR, with CMR only indicated when
echo is ‘unsatisfactory’.3,33 Using a left ventricular end-systolic linear
dimension (LVESd) >40mm on echo is however inherently ‘unsatis-
factory’ as a guide to intervention, as it is a poor marker of end-
systolic volume in primary MR due to the preferential spherical
remodelling process that takes place at the apex and mid-ventricular
level.34 On the other hand, accurate CMR volumes may be sufficient
to monitor patients, since an indexed LVEDV of <100mL/m2 from a
single baseline CMR conveyed a 90% surgery-free survival rate at
5 years.32 Recognising that delaying surgery until the onset of ven-
tricular dysfunction with left ventricular ejection fraction (LVEF)
<60% or LVESd >40mm, may be associated with an outcome pen-
alty,35,36 the recent AHA/ACC focused update have introduced an
additional Class IIa indication as progressive deterioration in LVEF or
LVESd on serial imaging.37 Finally, mitral regurgitant volume:LVEDV
ratio, which is best measured on CMR, has been proposed as an use-
ful indicator that can detect the presence of excessive ventricular
dilatation for the degree of MR, thereby highlighting the presence of
additional myopathic processes such as ischaemia.38 Furthermore,
reminiscent of animal models of volume overload where cardiac de-
compensation contributed to further increases in LVEDV in the pres-
ence of static volume overload (Supplementary data online, Table
S2),39 it is reasonable to hypothesize that longitudinal regurgitant vol-
ume: LVEDV ratio measurements may be able to identify
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..asymptomatic primary MR patients who are in the early transitional
stages of decompensation. For now, although it is not known
whether serial imaging by CMRwould result in improved patient out-
comes compared with echo, the acknowledged greater reliability of
CMR volumetric measurements argues for more routine use in
surveillance.
LVEF is problematic in MR, whether measured by echo or CMR, as it
is a measure of chamber function that is affected by changes in loading
conditions. In recognition of this inherent weakness in serial LVEF, recent
efforts have focused on identifying more sensitive ‘sub-acute’ markers of
LV impairment. These include echo based tissue Doppler (TDI) for
measurement of myocardial systolic and diastolic velocities (TDI),40 2D
Figure 1 The relative benefits of echocardiography and cardiac magnetic resonance in the management of primary degenerative mitral
regurgitation.
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Table 1 Example cases highlighting the differing benefits of echo vs. CMR
Case 1: 20-year-old $ Case 2: 69-year-old $ Case 3: 45-year-old # Case 4: 45-year-old #
Moderate on TOE Severe on TOE Severe on TOE MV anatomy
Severe on CMR Moderate on CMR Severe on CMR Echo vs. CMR
Bileaflet myxomatous degeneration
resulting in holosystolic CW
Doppler, systolic flow reversal in
RUPV. MR jet is posteriorly
directed, wrapping around LA. VC
6mm.
Bileaflet myxomatous degeneration
resulting in multiple jets. MR is mainly
anteriorly directed (VC area 79mm2,
systolic flow reversal in RUPV, PISA
radius 10mm, LV SVol - LVOT SVol
= 60mL)
Complex valve lesion with flail A3/P3
scallops from chordal rupture, involv-
ing the posteromedial commissure.
EROA 70mm2, LV SVol - LVOT SVol
= 104mL, systolic flow reversal in
LUPV.
Severe MR due to flail P2/P3 with
ruptured secondary chord (arrows)
from posteromedial papillary
muscle. PISA 14mm, LV SVol -
LVOT SVol = 68mL, systolic flow
reversal in LUPV.
Colour Doppler Colour Doppler Colour Doppler CMR en-face valve view
CMR - end systole CMR - end diastole CMR - aortic flow A2P2 and A3P3 scallops
BSA 1.87; LVEDVi 98mL/m2; LVESV
26mL/m2; LVSV 133mL; LVEF 73%;
AVflow 80mL; LA volume 43mL/
m2; MRvol 55mL; MRfraction 41%.
BSA 1.77; LVEDVi 76mL/m2 LVESVi
18mL/m2; LV SV 102mL; LVEF 76%;
AVflow 72mL; MRvol 30mL;
MRfraction 30%.
BSA 2.5; LVEDVi 88mL/m2; LVESVi
21mL/m2; LVSV 169mL; LVEF 76%;
MRvol 77mL; MRfraction 46%.
Discussion points: Case 1: VC of 6mm suggests moderate MR with CMR quantification demonstrating borderline severe MR. Note that the additional end-systolic LV volume
below leaflets and above MV annulus (shaded area) in extensive prolapses may not be accounted on Simpson’s biplane, but can be taken into account on a CMR short-axis
stack. Case 2: Multiple jets of severe MR visualized on TOE, but repeated longitudinal CMR measuring only moderate MR. Case 3: Agreement between echo and CMR despite
the presence of complex MR with commissure involvement. Case 4: Echo remains gold standard for MV anatomy assessment. Scallops can be visualized on CMR using dedi-
cated valve planes, but there is neither 3D visualization nor sufficient spatial resolution for chordal characterization.
AVflow, aortic valve flow; BSA, body surface area; CW, continuous wave; LUPV, left upper pulmonary vein; LVEDVi, left ventricular end-diastolic volume index; LVESVi, left
ventricular end-systolic volume index; MRfraction, mitral regurgitant fraction; MRvol, mitral regurgitation volume; RUPV, right upper pulmonary vein; SVol, stroke volume.
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..speckle tracking echo for measurement of strain, strain rate, and tor-
sion,41 and the CMR equivalents that include grid-tagging and feature/tis-
sue tracking. The Holy Grail of all techniques is to measure detect sub-
clinical LV dysfunction in primary MR42 although all are affected by load-
ing conditions and none are yet included in current valve guidelines.43
Therefore, at present, accurate and reliable measurement of volumes
and ejection fraction remain at the centre of management of patients
with asymptomatic primary MR and highlights an important area where
CMR can be complementary to existing management pathways.
The left atrium
Left atrium (LA) volume above 60mL/m2 on echo has become a
Class IIA indication for MV surgery in the European guidelines, al-
though 2D TTE appears to under-estimate size compared with a 3D
CMR approach.44 A multi-slice short-axis volumetric approach on
CMR is considered the gold standard for structural assessment of the
LA (Supplementary data online, Table S3) with more accurate and re-
liable measurement again arguing for a greater role.
Pulmonary hypertension and the right
heart
The onset of pulmonary hypertension represents an adverse compli-
cation of MR and a resting peak pulmonary artery systolic pressure
(PASP) >50mmHg on echo is a Class IIA indication to repair.1,2
Although questions have been raised about the accuracy of PASP by
echo45 and the general estimation of the probability of pulmonary
hypertension has not been tested in primary MR,46 CMR methods of
measuring pressure are not in routine use.47,48 The main benefit of
CMR at present lies in assessment of RV chamber size, function, and
hypertrophy.49 Doppler measurement of TR Vmax remains central to
the management of primary MR and the role of CMR in quantification
of RV size and function is supportive only.
Current limitations and future
directions
CMR remains a modality which is less readily available than echo in
many centres and which demands expertise. The most commonly
used sequences require acquisition over several cardiac cycles and
employ breath-holding that some patients cannot manage, although
alternatives are now available that cover the entire LV in a fraction of
the time and without need for breath-holding.50 There is no current
direct method to quantify MR severity by CMR and much of the data
that compare accuracy of techniques in determining outcomes are
derived from small, often single centre studies that do not all
Table 2 Current guideline indications for CMR and TTE and proposed additive value of CMR to these
recommendations
Current recommendations for CMR
(1) Assessment by echo is unsatisfactory
(2) Discrepancy between MR severity and clinical findings
• ASE/SCMR 2017
• ESC/EACTS 2012
• AHA/ACC 2014
Current recommendations for TTE
(1) Moderate MR and preserved LV function requires echocardiographic assessment every 1–2 years
(2) Severe MR and preserved LV function requires echocardiographic assessment every 6–12months
• ESC/EACTS 2012
• AHA/ACC 2014
Revised recommendations for CMR
(1) Unsatisfactory assessment by echo, specifically:
a. Indeterminant ‘moderate-severe’ MR.
b. Inability to perform quantitative measurement of MR by echo when severe MR cannot be definitively included or excluded.
c. Borderline ventricular function (LVEF 55–65%) in moderate–severe MR.
d. Fall in LVEF below 60% in asymptomatic patients, where a change of <10% has occurred compared to the previous echocardiographic study.
(2) Discrepancy between clinical, exercise, and echo findings (including stress):
a. Symptoms with moderate MR and preserved LV function.
b. Moderate MR with impaired or dilated LV.
(3) Routine use of CMR:
a. Moderate MR patients as baseline reference for LV size and function.
b. Every 12–24months for severe MR with preserved LV function (interdigitating with TTE to give imaging assessment every 6–12months
by one modality).
Future of CMR imaging in MR?
(1) Markers of adverse LV remodelling:
a. Strain imaging with tagging or tissue tracking.
b. Fibrosis imaging with LGE and T1/ECV mapping.
(2) 4D flow phase-contrast CMR
ECV, extra-cellular volume; LGE, late gadolinium enhancement.
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.demonstrate a consistent advantage using CMR.51 However, CMR
offers a unique ability to characterize the myocardium and try to un-
ravel the individual myocardial response to chronic MR and help iden-
tify those ‘more vulnerable’ to adverse remodelling. Histological
evaluation has shown fibrosis on biopsy and CMR techniques of late
gadolinium enhancement and T1 mapping allow detection of both ir-
reversible coarse replacement fibrosis and diffuse interstitial fibrosis,
independent of loading conditions (Supplementary data online, Table
S3). In a cross-sectional study of 35 asymptomatic patients with
moderate-severe MR and LVEF >60%, diffuse interstitial fibrosis as
measured by ECV above 30% was detected in approximately one-
third of subjects.52 Serial data are needed to determine whether this is
associated with decline in LV function or adverse remodelling after
surgery and results from on-going prospective studies may help.53
The implications of myocardial fibrosis in MR extends beyond ven-
tricular function. There is evidence suggesting that both LGE and dif-
fuse interstitial fibrosis visualized on T1 mapping can predispose to
complex ventricular arrhythmias and sudden cardiac death in primary
MR.54,55
Summary: when should you do a
CMR for MR?
Any assessment of a patient attending with primary MRmust include a
detailed echocardiogram using high-quality 2D and 3D imaging to de-
fine the aetio-pathogenesis, involving careful assessment of the leaflets,
annulus, chords, and papillary muscles. CMR plays a secondary role in
this regard. In the assessment of severity of MR, echo may be sufficient
in many cases, but CMR can quantify regurgitation in more cases than
2D or 3D and does so with greater reliability. There appears to be a
tendency for echo to over-estimate severity of MR and there are data
to suggest that CMR measures may deliver better long-term out-
comes, although prospective CMR-based interventional studies are
lacking. At present, there are sufficient data not only to support the
use of CMR where 2D or 3D echo is incomplete, or results are inde-
terminate but also to promote a greater role in an integrated surveil-
lance and surgical timing programme for patients with moderate-
severe MR. CMR has a recognized primacy compared to 2D echo in
measurement of LV volumes and ejection fraction, not least due to
the limitations of linear measurements on 2D or M-mode in primary
MR. This accuracy suggests that CMR should have a bigger part in
monitoring, independent of its advantages in measuring atrial and
right-sided volumes. In the future, more comparative research is
needed to define the roles of each modality against outcomes in pro-
spective studies, and this should also seek to confirm or refute the util-
ity of advanced echo techniques and tissue characterization by CMR.
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